Skip to main content

Peer Review reports

From: Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

Original Submission
21 Oct 2021 Submitted Original manuscript
21 Nov 2021 Reviewed Reviewer Report
6 Jan 2022 Reviewed Reviewer Report
4 Feb 2022 Reviewed Reviewer Report
25 Feb 2022 Author responded Author comments - Karan Pattni
Resubmission - Version 2
25 Feb 2022 Submitted Manuscript version 2
2 Mar 2022 Author responded Author comments - Karan Pattni
Resubmission - Version 3
2 Mar 2022 Submitted Manuscript version 3
Publishing
3 Mar 2022 Editorially accepted
20 Mar 2022 Article published 10.1186/s12879-022-07239-z

You can find further information about peer review here.

Back to article page